Skip to main content
Fig. 1 | Experimental Hematology & Oncology

Fig. 1

From: Outcomes of acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: validation, comparison and improvement of 2022 ELN genetic risk system

Fig. 1

Patients and genetic characteristics and impact of ELN-2022 and ELN-2017 risk stratification on clinical outcomes. A Relationship of risk groups between ELN-2022 and ELN-2017 risk groups; B Distribution of re-stratification in ELN-2017 risk groups. C Landscape of genetic abnormalities defined by ELN-2022 genetic risk categories. The color scale is representative of a number of patients. D Additional mutations stratified by ELN-2022 genetic risk categories. Genes mutated in more than ten patients are shown. E Overall survival stratified by ELN-2022 risk categories. F Overall survival stratified by ELN-2017 risk categories. G Cumulative incidence of relapse stratified by ELN-2022 risk categories. H Cumulative incidence of relapse stratified by ELN-2017 risk categories

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us